“Dr. Johnson is an experienced industry leader with extensive knowledge of the current regulatory landscape, in the United States and around the world.” said Slone Partners CEO Leslie Loveless.
SOUTH RIDING, Va. (PRWEB) December 01, 2020
Slone Partners, a nationwide executive search firm for life science, biotechnology, and diagnostics companies, has announced the placement of Kevin B. Johnson, Ph.D., MBA, as Senior Vice President of Regulatory Affairs at Inozyme Pharma. In his new role, Johnson is responsible for leading Inozyme’s global regulatory strategy.
Johnson brings to Inozyme more than 25 years of experience in developing and implementing global regulatory and clinical development strategies for rare diseases across entire product development lifecycles from preclinical through clinical development and ultimately to product approval for a variety of drugs, biologics, combination products and cell/gene therapies. Most recently, he served as Senior Vice President, Head of Regulatory and Quality, at Magenta Therapeutics, where he led the company’s global strategy for a portfolio of biologics. He has also served in senior management positions at Imara, Vtesse (later acquired by Sucampo, which was later acquired by Mallinckrodt Pharmaceuticals), and GlaxoSmithKline.
“Dr. Johnson is an experienced industry leader with extensive knowledge of the current regulatory landscape, in the United States and around the world.” said Slone Partners CEO Leslie Loveless. “He will be a tremendously valuable addition to the Inozyme executive team at a time when the company is moving aggressively to develop and bring to market the most advanced set of therapeutic breakthroughs for patients living with rare diseases.”
“We are thrilled to have Kevin join the Inozyme leadership team during this period of steady execution and as we prepare to enter clinical development,” said Axel Bolte, MSc, MBA, Co-founder, President and Chief Executive Officer of Inozyme Pharma. “Kevin is a talented regulatory affairs executive with deep experience in rare diseases and I look forward to Kevin’s contributions in helping Inozyme meet the needs of underserved patient communities.”
Johnson holds a Ph.D. in Neurobiology from the University of North Carolina School of Medicine, an MBA from the Kenan-Flagler School of Business at the University of North Carolina, and a B.S. in Chemistry from the University of South Florida. He also holds a Regulatory Affairs Certification (RAC) credential from the Regulatory Affairs Professional Society.
ABOUT SLONE PARTNERS
Slone Partners delivers the leaders who build amazing and diverse life sciences organizations – People Are Our Science®. Founded in 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established biotech, diagnostics, research tools, healthcare, precision medicine, CRO, and laboratory services companies. With coast-to-coast presence in the most active healthcare industry hubs of Boston, San Francisco, New York, Los Angeles, San Diego, Austin, Research Triangle Park NC, and Washington DC, Slone Partners uniquely and precisely provides an array of executive search and advisory services, including diversity, equity, and inclusion strategy, to innovative life sciences companies. To learn more about Slone Partners’ value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.
ABOUT INOZYME PHARMA
Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. For more information, please visit http://www.inozyme.com.